Species |
Mouse |
Protein Construction |
IL-2 R alpha/CD25 (Glu22-Lys236) Accession # P01590 |
His |
N-term |
C-term |
|
Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
Endotoxin Level |
Less than 1EU per μg by the LAL method. |
Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized IL-2 R alpha/CD25, His, Mouse at 5μg/ml (100μl/well) on the plate can bind Biotinylated Mouse IL2, His Tag. Test result was comparable to standard batch. |
Expression System |
HEK293 |
Theoretical Molecular Weight |
25.76 kDa |
Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 50-70 kDa based on Bis-Tris PAGE result. |
Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |

Immobilized IL-2 R alpha/CD25, His, Mouse, His Tag at 5 μg/ml (100 μL/well) on the plate. Dose response curve for Biotinylated Mouse IL-2, His Tag with the EC50 of 0.17 μg/ml determined by ELISA.

The purity of IL-2 R alpha/CD25, His, Mouse is greater than 95% as determined by SEC-HPLC.

IL-2 R alpha/CD25, His, Mouse on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
Target Background |
Human IL-2 receptor alpha (IL-2 R alpha), also known as Tac antigen and as CD25, was initially identified as a 55 kDa membrane glycoprotein that is capable of binding IL‑2.eceptor for interleukin-2. The receptor is involved in the regulation of immune tolerance by controlling regulatory T cells (TREGs) activity. TREGs suppress the activation and expansion of autoreactive T-cells. |
Synonyms |
CD25; IDDM10; IL-2 R alpha; IL2R; IL2RA; p55; TCGFR |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.